Introducing
Prezi AI.
Your new presentation assistant.
Refine, enhance, and tailor your content, source relevant images, and edit visuals quicker than ever before.
Trending searches
Loading…
1
Transcript
6 February 2019
Early History
Early
History
Acquisitions 1960's
The beginning
- SLE - Salomon, Levine and Elstein
- European Immigrants
Jerusalem 1901
1935
- Dr. Gunther Friedlander
- Teva Middle East Pharmaceutical &
Chemical Works Co. Ltd
Jerusalem 1935
- IPO in newly founded Tel-Aviv Stock Exchange
1951
Jerusalem 1901
ASIA + ZORI + TEVA
Jerusalem 1935
1951
1964-1968
Jerusalem 1901
Eli Hurvitz
1976
1976
Group changes it official name:
Teva Pharmaceutical Industries
Competitive advantage
Building Foundation
Competitive advantage
Arab Boycott
"Without the Arabic boycott, our company wouldn't exist"
PLANTEX
MIGADA
Building Foundation
- Backward integration- API
- Winning the Israeli market
- Expanding portfolio
- Infrastructure for the US market
Footprint in USA
USA First Footprint
- Generic market new regulation
- FDA approval at the 80's
- Gain shares- JV with W.R grace
Becoming Global
Global Growth
Aggressive Acquisitions
Aggressive Acquisitions
- Expertise in acquisitions & integration
* Expanding investments to Europe
Sales Strategy
"No one takes market shares - no one."
- Unique distribution strategy
- Price strategy
- Tax exempt - Israel
Market share lead in USA
- number of prescription
Global sales
From 90's to 2000's
Revenue increased from 295M$ to 1.75B$
Europe
USA
Israel
From To
9% 26%
From To
33% 64%
From To
57% 6%
Rest of the world
From To
1% 4%
Innovative
TEVA start to invest in R&D and enters the innovative market
- Copaxone - Weizmann Institute of Science
- Research for MS cure - 1967
- FDA approved- 1996
Management
Management, Management, Management
Volatility
Commercialization of COPAXONE
COPAXONE Sales development
Investment in R&D
Teva investments in R&D
Is it enough in order to create future pipeline?
Mega acquisitions
$40.5
Mega acquisitions
2006
2011
2014
2015
Standing on one foot?
Standing on one foot?
TEVA's profit structure
Financials
Revenue
Stock Trend
60$
30$
10$
Management Changes
Israel Makov 2002
Erez Vigodman
2014
Yitzhak Peterburg
2017T
Shlomo Yanai 2007
Jeremy Levin 2012
Eyal Deshe
2013T
Kåre Schultz
2017
Where to?
Where to ?
Debt & financing
Net Debt Development
Phase 2
Restructuring
Restructuring
10
13
40
$3b
offices and laboratories closed
manufacturing sites closed or divested
spend base reduction achieved
manufacturing sites being closed or divested
* Full operational capacity maintained
Future growth
Future growth
Europe
USA
China
So...?
Choose a template
Presentations from around the world
Learn more about creating dynamic, engaging presentations with Prezi